| abstract |
The present invention relates to (a) (1) L1 virus-like particles (VLPs) of human papilloma virus (HPV) type 16, L1 VLPs of HPV type 18, or a combination thereof; And (ii) deacylated nontoxic Lipooligosaccharides (LOS); And (b) a human cervical cancer vaccine pharmaceutical composition comprising a pharmaceutically acceptable carrier; And it relates to a method for producing human papilloma virus (HPV) L1 virus-like particles (VLP). The cervical cancer vaccine composition of the present invention is superior to Cervarix ™ and Gardasil ™ in both Th1 type immune response (cellular immunity) and Th2 type immune response (humoral immunity) in immunity against HPV, and thus excellent efficacy as a cervical cancer vaccine. Exert.n n n n Human papilloma virus, L1, VLP, vaccine, LOS |